Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABSW) Operating Expenses (2020 - 2025)

SAB Biotherapeutics' Operating Expenses history spans 6 years, with the latest figure at $15.8 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 55.78% year-over-year to $15.8 million; the TTM value through Dec 2025 reached $49.0 million, up 10.67%, while the annual FY2025 figure was $49.0 million, 10.67% up from the prior year.
  • Operating Expenses reached $15.8 million in Q4 2025 per SABSW's latest filing, up from $12.7 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $21.1 million in Q2 2021 to a low of $6.6 million in Q2 2023.
  • Average Operating Expenses over 5 years is $13.0 million, with a median of $11.9 million recorded in 2022.
  • Peak YoY movement for Operating Expenses: soared 204462.97% in 2021, then tumbled 56.87% in 2023.
  • A 5-year view of Operating Expenses shows it stood at $18.4 million in 2021, then crashed by 45.55% to $10.0 million in 2022, then soared by 91.39% to $19.2 million in 2023, then tumbled by 47.21% to $10.1 million in 2024, then soared by 55.78% to $15.8 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Operating Expenses are $15.8 million (Q4 2025), $12.7 million (Q3 2025), and $9.7 million (Q2 2025).